Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders

Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders

Case–control observational studies suggested that aspirin might prevent hepatocellular carcinoma (HCC) in high-risk patients, even if randomized clinical trials are lacking. Information regarding aspirin in subjects who already developed HCC, especially in its advanced stage, are scarce. While aspir...

Full description

Bibliographic Details
Main Authors: Luca Ielasi, Francesco Tovoli, Matteo Tonnini, Raffaella Tortora, Giulia Magini, Rodolfo Sacco, Tiziana Pressiani, Franco Trevisani, Vito Sansone, Giovanni Marasco, Fabio Piscaglia, Alessandro Granito
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
hepatocellular carcinoma
liver cirrhosis
liver cancer
aspirin
outcome
sorafenib
Online Access:https://www.mdpi.com/2072-6694/13/24/6376

Similar Items

Similar Items